ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

HALO Halozyme Therapeutics Incorporated

38,10
-0,67 (-1,73%)
Após o horário de negociação
Última atualização: 17:22:55
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Halozyme Therapeutics Incorporated HALO NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
-0,67 -1,73% 38,10 17:22:55
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
38,54 37,965 39,03 38,11 38,77
mais cotações »

Notícias Recentes

Data Hora Fonte Título
25/04/202417:45PRNUSMahesh Krishnan Elected to Halozyme's Board of Directors
23/04/202409:30PRNUSHalozyme to Report First Quarter 2024 Financial and..
27/02/202410:30PRNUSHalozyme to Participate in Upcoming Investor Conferences
20/02/202418:01PRNUSHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL..
08/02/202418:30PRNUSHalozyme To Report Fourth Quarter and Full Year 2023..
29/01/202418:15PRNUSHalozyme Announces Takeda Received European Commission..
18/01/202410:30PRNUSHalozyme Announces argenx Received Approval in Japan for..
16/01/202410:15PRNUSHalozyme Announces Takeda Receives FDA Approval for HYQVIA®..
16/01/202403:15PRNUSHalozyme Announces Roche Receives European Commission..
12/01/202411:25PRNUSHalozyme to Host Investor Business Forum and Long-Term..
27/11/202310:00PRNUSHalozyme to Present at Upcoming Investor Conferences
16/11/202311:00PRNUSHalozyme Announces argenx Receives European Commission..
06/11/202318:01PRNUSHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING..
06/11/202309:30PRNUSHalozyme and Acumen Pharmaceuticals Enter Global..
30/10/202319:35PRNUSHalozyme To Report Third Quarter 2023 Financial and..
19/10/202308:15PRNUSPositive Topline Results Reported from Bristol Myers..
16/10/202316:05PRNUSUpdate: Halozyme Announces Presentation of Positive Clinical..
16/10/202309:00PRNUSHalozyme Announces Positive Clinical Data of its High-Volume..
31/08/202309:30PRNUSHalozyme to Present at Upcoming Investor Conferences
29/08/202305:50PRNUSHalozyme Announces Approval of Roche's Tecentriq®..
08/08/202317:01PRNUSHALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING..
25/07/202309:30PRNUSHalozyme To Report Second Quarter 2023 Financial and..
17/07/202302:15PRNUSPositive Topline Data Reported from argenx's ADHERE Study of..
13/07/202302:15PRNUSPositive Results Announced from Phase 3 OCARINA II Trial..
20/06/202319:30PRNUSHalozyme Announces argenx Receives FDA Approval for VYVGART®..
06/06/202309:30PRNUSHalozyme to Present at the Goldman Sachs 44th Annual Global..
09/05/202317:01PRNUSHALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING..
03/05/202309:30PRNUSHalozyme to Present at Upcoming Investor Conferences

Seu Histórico Recente

Delayed Upgrade Clock